OAT-4828: USP7 Inhibitor Discovery Data

Jacek Chrzanowski published data on the structure-guided discovery of OAT-4828, a potent and selective USP7 inhibitor. The dataset likely contains results from the compound's optimization, pharmacokinetic profile in mice, and preliminary safety assessments. The data was last updated on May 6, 2026.

Use Cases

• Training predictive models for compound potency based on structural modifications described in the study.
• Analyzing pharmacokinetic profiles of lead compounds based on the mouse model data mentioned.
• Evaluating structure-activity relationships for USP7 selectivity based on the described optimization process.
• Benchmarking in vivo antileukemic activity based on the syngeneic B-cell lymphoma model results.

Strengths

• Data is associated with a published scientific discovery process, as described in the detailed summary.
• The dataset includes results from in vivo testing in a mouse model of non-Hodgkin lymphoma.

Limitations

• The dataset is very small at 3.8 KB, indicating limited scope and likely a summary of key results rather than raw experimental data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Structure-based drug design and in vivo pharmacological testing, as described.

Freshness

Last updated 2026-05-06 19:03:53; freshness should be verified.